5.2 Tirzepatide (SURMOUNT Trials) Tirzepatide demonstrated even greater mean weight loss in SURMOUNT trials. Findings included: Weight reductions exceeding 20% in some cohorts Dose-dependent gastrointestinal symptoms Lean mass reduction proportional to total weight loss Again, detailed micronutrient panels were not central trial endpoints
It seems quite odd to me that the GLP one program would not cover diabetes patients who could use this as a sugar reduction tool
Finally, we thank our funding sources: Genome Canada and Genome BC (275SIL and 298SGC), Canadian Institutes of Health Research (GP1-155868), BC Childrens Hospital Research Institute and BC Childrens Hospital Foundation, Illumina (in-kind), Provincial Health Services Authority, Alberta Children's Hospital Foundation and Canadian Rare Diseases: Models & Mechanisms Network (RDMM)
Kalivas, P
In cancer (Table 1), CDO1 is usually silenced by promoter methylation and this is associated with poor prognosis, 70,74 implying that the shutting down of CDO1 expression favours cancer progression
I don't really want him on therapeutic testosterone because if he injects it, he can have an inflammatory response or inflammatory cascade to the actual injection of the testosterone because he has so much visceral fat, which is, you know, causing all the cellular inflammation
.jpg)
